# t(11;14), cyclin D1 and SOX11

Source: https://onco.cc/terms/cyclin-d1-t11-14/  
OnCo record `cyclin-d1-t11-14` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The t(11;14) translocation parks the cyclin D1 gene next to the antibody gene's accelerator, flooding the cell with a protein that pushes it through division; a brown nuclear stain for cyclin D1 (plus SOX11) is how mantle cell lymphoma is confirmed, and in myeloma the same translocation marks the patients who respond to venetoclax.

## Summary

What is measured: the IGH::CCND1 translocation and the proteins that go with it. How: cyclin D1 immunohistochemistry (nuclear staining in over 95 percent of mantle cell lymphomas; the rare negatives carry CCND2 or CCND3 rearrangements and are caught by SOX11 positivity), FISH for CCND1::IGH on tissue, blood or marrow, karyotype, and SOX11 immunohistochemistry, which is positive in classic nodal mantle cell lymphoma and negative in the indolent leukaemic non-nodal form (IGHV-mutated, often CD5-negative). In myeloma, FISH panels find t(11;14) in 15 to 20 percent, a standard-risk lesion whose cells depend on BCL2, and more often in AL amyloidosis and plasma cell leukaemia. What a result changes: it separates mantle cell lymphoma from CLL and small lymphocytic lymphoma (cyclin D1-negative, LEF1-positive) and follicular lymphoma; SOX11-negative leukaemic non-nodal disease can often be observed; in myeloma, t(11;14) selects patients for venetoclax-based regimens (a BELLINI subgroup, CANOVA, and NCCN listing off label) and predicts BCL2-inhibitor response in AL amyloidosis. Where it matters: mantle cell lymphoma, plasma cell leukaemia and relapsed myeloma.

## Fields

- Kind: Term
- Last checked: 2026-09-17
- Also known as: t(11;14)(q13;q32); CCND1 translocation; CCND1::IGH; IGH::CCND1; cyclin D1; cyclin D1 immunohistochemistry; cyclin D1-positive; cyclin D1-negative mantle cell lymphoma; SOX11; SOX11-negative; leukaemic non-nodal mantle cell lymphoma; t(11;14) myeloma; CCND1-translocated myeloma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cyclin_D1
- Wikipedia: https://en.wikipedia.org/wiki/Cyclin_D1

## Connected records

- terms: [Cytogenetics and karyotype](https://onco.cc/terms/cytogenetics/), [FISH / ISH (in situ hybridisation)](https://onco.cc/terms/fish/), [High-risk cytogenetics (myeloma)](https://onco.cc/terms/high-risk-myeloma/), [Immunohistochemistry (IHC)](https://onco.cc/terms/ihc/), [MIPI (Mantle Cell Lymphoma International Prognostic Index)](https://onco.cc/terms/mipi/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [CDK4/6](https://onco.cc/targets/cdk4-6/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Plasma cell leukaemia](https://onco.cc/cancers/plasma-cell-leukaemia/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)

---
JSON: https://onco.cc/api/v1/entities/cyclin-d1-t11-14.json